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ABSTRACT
Objectives: To compare the effectiveness of in-
hospital medical therapy versus coronary
revascularisation added to medical therapy in patients
who stabilised after an acute coronary syndrome (ACS).
Design: Propensity score-matched cohort study from
the database of the Tampere ACS registry.
Setting: A single academic hospital in Finland.
Participants: 1149 patients with a recent ACS, but no
serious coexisting conditions: recurrent ischaemic
episodes despite adequate medical therapy,
haemodynamic instability, overt congestive heart failure
and serious ventricular arrhythmias.
Primary and secondary outcome measures: The
composite endpoint of major acute cardiovascular
events (MACEs): unstable angina requiring
rehospitalisation, stroke, myocardial infarction and all-
cause mortality, at 6-month follow-up.
Results: Compared with standard medical treatment,
revascularisation was associated with a lower rate of
MACEs at 6 months in patients of the first quintile (HR
0.81; 95% CI 0.66 to 0.99), but a higher rate of
MACEs in the fifth quintile (HR 4.74, CI 1.36 to 16.49;
p=0.014). There were no significant differences in the
rates of MACEs in the remaining three quintiles.
Patients of the first quintile were the oldest (79.7
±8.3 years) and had a more significant (p<0.001)
history of prior myocardial infarction (37%) and poor
renal function (creatine, µmol/l: 114.9±70.7). They also
showed the highest C reactive protein (7.3±9.5 mg/l)
levels.
Conclusions: Our findings suggest that in-hospital
coronary revascularisation did not lead to any
advantage with signal of possible harm in the great
majority of patients who stabilised after an ACS. An
early invasive management strategy may be best
reserved for elderly patients having high-risk clinical
features and biochemical evidence of a strong
inflammatory activity.
INTRODUCTION
Within the field of clinical practice, it is
common knowledge that patients with acute
coronary syndromes (ACS) presenting with
recurrent ischaemic episodes despite aggres-
sive medical therapy, haemodynamic instabil-
ity, overt congestive heart failure or serious
ventricular arrhythmias may benefit from
early in-hospital coronary revascularisation.1–4
In contrast, it remains uncertain whether
patients whose condition can safely be stabi-
lised in the coronary care unit should
ARTICLE SUMMARY
Articles focus
▪ To examine the effects of coronary revascularisa-
tion therapy in patients who have stabilised after
an acute coronary syndrome (ACS), we used a
propensity score analysis6 7 based on the likeli-
hood of undergoing revascularisation after stabil-
isation. Propensity-stratum-specific analyses
were then used to evaluate the association of
in-hospital coronary revascularisation and major
acute cardiovascular events.
Key message
▪ The principal finding is that routine in-hospital
coronary intervention adds no benefit to medical
therapy for the great majority of patients.
Moreover, we found a significant reduction in
cardiovascular endpoints associated with revas-
cularisation, compared with medical treatment in
patients with oldest age prior to myocardial
infarction and renal failure and an increased
hazard in younger male patients with ST eleva-
tion myocardial infarction and a family history of
coronary disease
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routinely receive an interventional approach before hos-
pital discharge.
Previous studies lumped together patients with such
markedly different clinical characteristics.2 5–7 As a
result, they were unable to evaluate whether patients
who met stabilisation criteria also derived substantial
benefit from coronary revascularisation therapy.
The current study was undertaken to examine the
effects of coronary revascularisation therapy in patients
who had stabilised after an ACS.
METHODS
Study population and data collection
The Tampere University Hospital registry enrolment
region encompasses the city of Tampere and 11 neigh-
bouring municipalities. Between January 2002 and
March 2003, 1188 consecutives were included in the
Tampere University Hospital Registry. In February 2005,
the vital status was known for 1186 patients up to
302 days after recruitment.
The ethics committee at Tampere University Hospital
approved the study protocol. The patients gave their
written informed consent for participation. The diagno-
sis of ACS was based on symptoms, troponin I values and
ECG findings at admission. Troponin I values were col-
lected at baseline and after 6–12 h. Patients were cate-
gorised as ST segment elevation myocardial infarction
(STEMI) and Non-ST elevation acute coronary syndrome
(NSTACS). The definition of clinical stabilisation met
the criteria of the 2005 AHA Guidelines for cardiopul-
monary resuscitation and emergency cardiovascular
care.8 None of the enrolled patients performed primary
or rescue percutaneous coronary intervention (PCI).
Patients were excluded from the analysis if they had
recurrent ischaemic episodes despite adequate medical
therapy, haemodynamic instability, overt congestive heart
failure (Killip class III or IV) or serious ventricular
arrhythmias.9 To avoid survival bias—as patients who
were selected for the study would have to survive
enough to have the procedure—a landmark time was
used. We defined the landmark time as 2 days, based on
the fact that in the study cohort coronary revascularisa-
tion (PCI or coronary artery bypass grafting (CABG))
was performed 3–6 days after admission. After excluding
37 patients for the above reasons, the final analysis
population was 1149 particicpants whose symptoms had
resolved by the time of evaluation.
The following data were collected for all patients
during hospitalisation: demographic characteristics (age
and gender), cardiovascular risk factors (smoking,
family history of coronary artery disease), coexisting
medical condition (hypertension, hyperlipidaemia, dia-
betes, Canadian Cardiovascular Society functional classi-
fication of angina before the acute phase), clinical
characteristics at admission (blood pressure, heart rate,
ECG findings, troponin I values, C reactive protein,
blood lipids, serum creatine), medications (at hospital
admission, during hospital stay and at discharge) and
in-hospital cardiac procedures (angiography, PCI or
CABG).
Treatment decisions
The decision whether or not to perform coronary revas-
cularisation was left to the discretion of the treating
physician.
End-points
The primary measure of outcome was the composite
end-point of major acute cardiovascular events
(MACEs): unstable angina requiring rehospitalisation,
stroke, non-fatal myocardial infarction and all-cause mor-
tality at 6-month follow-up. End-points were mutually
exclusive and hierarchical as listed above. The outcomes
were assessed from the landmark time. A study nurse
contacted all patients alive by telephone to collect
follow-up data. Causes of death were registered from offi-
cial statistics.
Statistical analysis
We compare the clinical characteristics and outcome of
patients who did and did not undergo in-hospital revas-
cularisation. Results are presented as the mean±SD, or
median (IQR) for continuous variables and as the per-
centage for categorical variables. Categorical data were
analysed with between-group comparisons using the χ2
test. The Wilcoxon rank sum test and the analysis of vari-
ance test were used to compare the two groups on con-
tinuous variables.
A propensity analysis was carried out by use of a logis-
tic regression model for treatment with early-invasive
management (in-hospital revascularisation and medical
therapy) versus conservative strategy (medical therapy
alone). Multiple logistic regression with an in-hospital
revascularisation condition as a dependent variable was
used in the development of the propensity score.
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The strength of the current study was to focus on those
patients whose condition can safely be stabilised in the coron-
ary care unit providing key contextual data for identifying
patients with poor outcomes likely to benefit from coronary
revascularisation therapy, as well as providing initial estimates
of the efficacy of therapy.
▪ Our study should be interpreted in the context of several
potential limitations. First, this study has no power to detect
differences between treatment groups in the individual compo-
nents of the primary composite endpoint. Second, this ana-
lysis is not a randomised study. Although propensity score
helps to adjust for differences between groups, it does not
control for unmeasured differences in clinical care. However,
as a randomised trial cannot be carried out for every subgroup
of patients, an observational database is helpful in providing
hypothesis-generating data.
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Covariates were chosen using the approach described by
Blackstone.10 The final selected model included the fol-
lowing patient variables: age, gender, current or
ex-smoking, diabetes, previous myocardial infarction,
serum creatinine, systolic and diastolic blood pressure,
family history of coronary artery disease, Canadian
Cardiovascular Society functional classification of angina
before the acute phase (classes 1–4), troponin, C reactive
protein and index event (STEMI and NSTACS). The dis-
criminatory power of the logistic regression model was
measured by the area under the receiver operating char-
acteristic curve. After fitting the model, we ranked all
patients by their estimated propensity score and grouped
patients within quintiles. Differences in the selected vari-
ables among quintiles were examined using the Wilcoxon
rank sum test and the 2×2 χ2 test. We have corrected the
p value in multiple comparisons using the Bonferroni
procedure.
Event-free survival curves were estimated and plotted
on the basis of the Kaplan-Meier estimator. We calcu-
lated HR and 95% CI for 6-month MACEs, comparing
within each quintile patients who underwent revasculari-
sation and those who did not. The effect of quintile of
propensity score and treatment type on all-cause mortal-
ity and MACEs was evaluated by a multivariate Cox pro-
portional hazards regression model, which included an
interaction term between the two considered covariates.
Proportionality in hazard was carefully checked, both
with visual analysis of Schoenfeld residuals and with the
Grambsch-Therneau test. For the final model, multivari-
ate HRs have been presented along with their 95% CI.
Analyses were performed with the STATA V.8 statistical
software system.
RESULTS
Characteristics of the study population
The registry population consisted of 1149 patients (table 1).
Of these, 908 (79%) patients were managed only with
medical therapy alone and 241 (21%) patients were treated
with revascularisation (146 PCI and 95 CABG) and medical
therapy. MACEs occurred in 231 of these patients at
6-month follow-up (figure 1). Mortality from any cause
occurred in 169 patients, thus representing 73% of the
overall MACEs.
Propensity analysis
We ranked all patients by their estimated propensity
score and grouped patients within quintiles. The
median propensity score was 0.197 (IQR, 0.097–0.350).
The C-statistic for the propensity score model was
0.77, indicating a good discriminatory power. A sensible
match was found in all quintiles with the disappearance
of significant baseline differences within quintiles
Table 1 Characteristics of the study population sorted by in-hospital revascularisation
Variable Revascularisation
Number (n=908) Yes (n=241) p-Value
Age (years) 75 (65–81) 67 (58–74) <0.001
Male, n (%) 499 (55) 169 (70) <0.001
Diabetes, n (%) 245 (27) 51 (21) 0.07
Current or ex-smoking, n (%) 417 (46) 135 (56) 0.003
Hypertension, n (%) 490 (54) 125 (52) 0.46
Family history of CAD, n (%) 145 (16) 67 (28) <0.001
Previous myocardial infarction, n (%) 236 (26) 53 (22) 0.17
Total cholesterol (mmol/l) 4.6 (3.9–5.4) 4.7 (4.0–5.5) 0.19
LDL-cholesterol (mmol/l) 2.8 (2.1–3.3) 2.8 (2.3–3.4) 0.14
HDL-cholesterol (mmol/l) 1.1 (0.9–1.4) 1.1 (0.9–1.3) 0.08
Triglycerides (mmol/l) 1.3 (1.0–1.7) 1.5 (1.0–2.0) <0.001
Systolic blood pressure (mm Hg) 145 (125–167) 146 (127–167) 0.84
Diastolic blood pressure (mm Hg) 79 (68–90) 80 (70–91) 0.19
Creatine (µmol/l) 89 (73–113) 82 (71–98) 0.001
C reactive protein (mg/l) 13.3 (3.4–63.9) 9.8 (3.3–32.8) <0.001
Troponin I (µmol/l) 3.6 (0.5–21.7) 10.5 (1.7–35.2) <0.001
Canadian Cardiovascular Society, n (%) 0.77
No angina 490 (54) 125 (52)
Class 1 118 (13) 29 (12)
Class 2 200 (22) 58 (24)
Class 3 91(10) 24 (10)
Class 4 18 (2) 2 (1)
Index event, n (%) <0.001
ST-elevation myocardial infarction 236 (26) 96 (40)
Non-ST elevation-acute coronary syndromes 672 (74) 145 (60)
Values are expressed as median (IQR) where otherwise not indicated.
CAD, coronary artery disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
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between patients undergoing revascularisation and those
receiving medical therapy alone. The rate of revasculari-
sation increased from the first to the fifth quintile: 2.6%
(1.3% PCI and 1.3% CABG), 10.3% (4.5% PCI and
5.8% CABG), 12.5% (5% PCI and 7.5% CABG), 24.3%
(14.4% PCI and 9.9% CABG) and 50.3% (35.4% PCI
and 14.9% CABG), respectively. Conversely, the rate of
MACE decreased from the first to the fifth quintile:
52%, 47%, 40%, 29% and 21%, respectively).
Variables within each propensity score quintile are shown
in table 2. Propensity scoring by quintile failed to balance a
number of covariates across all quintiles. The most striking
imbalances in propensity scores occurred in the first and
fifth quintiles. The first quintile compared with all other
quintiles was characterised by very elderly patients, more
comorbid conditions, such as a history of prior myocardial
infarction, poor renal function (high creatine levels), high
C reactive protein levels and NSTACS. In contrast, the
patients of the fifth quintile compared with those of the
other quintiles were the youngest. They were prevalently
men and showed low C reactive protein levels.
They also had the highest proportions of STEMI
(50%) and a family history of coronary artery disease
(41.7%).
Table 2 Propensity score quintiles and baseline clinical characteristics
Quintile
n.1≤0.08377
(n. 230)
Quintile n.2
0.08378–
0.15536
(n. 229)
Quintile n.3
0.15537–
0.24783
(n. 230)
Quintile n.4
0.24784–
0.39149
(n. 230)
Quintile n.5
>0.39150
(n. 230)
p Value for
propensity
score analysis
Age (years) 79.7±8.3 74.2±10.4 73.3±9.6 67.3±10.1 58.9±10.9 <0.001
Male, n (%) 92 (40) 107 (46.7) 117 (50.9) 155 (67.4) 195 (85.2) <0.001
Current or
ex-smoking, n (%)
77 (33.4) 104 (45.4) 106 (46.1) 140 (60.8) 137 (59.6) <0.001
History of diabetes,
n (%)
81 (35.2) 75 (32.8) 42 (18.3) 59 (25.6) 39 (17) <0.001
History of
hypertension, n (%)
103 (44.8) 97 (42.4) 108 (47) 102 (44.3) 124 (53.9) 0.05
Family history CAD,
n (%)
17 (7.4) 27 (11.8) 27 (11.7) 45 (19.6) 96 (41.7) <0.001
Prior myocardial
infarction, n (%)
85 (37) 53 (23.1) 47 (20.4) 54 (23.5) 41 (17.8) <0.001
Systolic blood
pressure (mm Hg)
149.0±32.6 148.2±34.0 148.6±30.8 148.1±29.0 144.7±27.8 0.6
Total cholesterol
(mmol/l)
4.8±0.5 4.6±0.7 4.7±0.6 4.5±0.7 4.6±0.6 0.09
LDL-cholesterol
(mmol/l)
2.9±0.2 2.8±0.3 2.7±0.2 2.8±0.2 2.7±0.3 0.1
HDL-cholesterol
(mmol/l)
1.1±0.3 1.1±0.3 1.2±0.2 1.1±0.2 1±0.3 0.09
Diastolic blood
pressure (mm Hg)
78.0±19.5 79.4±17.5 80.9±16.8 81.8±17.9 82.4±16.3 0.06
Creatine (µmol/l) 114.9±70.7 97.2±53.0 79.6±26.5 70.7±17.7 70.7±17.7 <0.001
C reactive protein
(mg/l)
7.3±9.5 5.0±7.0 4.2±5.5 3.1±5.3 2.4±3.7 <0.001
Troponin I (µmol/l) 1.2±3.1 2.5±7.2 2.7±5.5 3.9±9.9 9.5±24.9 <0.01
No angina, n (%) 113 (49.1) 131 (57.2) 125 (54.4) 129 (56.2) 117 (50.9) 0.7
CCS 1, n (%) 35 (15.2) 20 (8.7) 33 (14.3) 33 (14.3) 21 (9.1)
CCS 2, n (%) 50 (21.7) 46 (20.1) 46 (20) 50 (21.7) 65 (28.2)
CCS 3, n (%) 24 (10.4) 25 (10.9) 21 (9.1) 17 (7.4) 25 (10.9)
CCS 4, n (%) 8 (3.6) 7 (3.1) 5 (2.2) 1 (0.4) 2 (0.9)
STEMI, n (%) 26 (11.3) 39 (17.0) 70 (30.4) 87 (37.8) 115 (50) <0.001
NSTACS, n (%) 204 (88.7) 190 (83) 160 (69.6) 143 (62.2) 115 (50) <0.001
Medical therapy, n
(%)
224 (97.4) 205 (89.7) 201 (87.5) 174 (75.7) 114 (49.6)
Coronary
revascularisation, n
(%)
6 (2.6) 24 (10.3) 29 (12.5) 56 (24.3) 116 (50.4)
Values are expressed as median±SD where not indicated otherwise.
CAD, coronary artery disease; CCS, Canadian Cardiovascular Society; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NSTACS,
non-ST elevation acute coronary syndrome; STEMI, ST-elevation myocardial infarction.
4 Bugiardini R, Eskola M, Huhtala H, et al. BMJ Open 2013;3:e002559. doi:10.1136/bmjopen-2013-002559
Coronary revascularisation in acute coronary syndromes
 group.bmj.com on April 26, 2013 - Published by bmjopen.bmj.comDownloaded from 
Propensity-stratum-specific effects
For MACEs, gradients across levels of the propensity
score for the treated and untreated groups were strong
and unexpectedly different. In the first quintile, use of
revascularisation was associated with the lowest rates of
MACEs as compared with medical therapy (15% vs
28.7%). In contrast, for the fifth quintile, the rates of
MACEs were 13.8% and 6.1% in the revascularisation
and medical therapy groups, respectively. There were
less striking differences in the rates of MACEs in the
remaining categories of propensity scores (second quin-
tile: 25% vs 25.3%; third quintile: 35.4% vs 20.3%;
fourth quintile: 10.7% vs 13.5%). Table 3 summarises
information about the HR of patients who had MACEs
during follow-up in the coronary revascularisation group
according to percentiles of the propensity score.
Compared with standard medical treatment, revasculari-
sation was associated with a lower rate of MACEs at
6 months in patients of the first quintile (HR 0.81; 95%
CI0.66 to 0.99; p=0.041), but a higher rate of MACEs in
the fifth quintile (HR 4.74; 95% CI 1.36 to 16.49;
p=0.014). There were no significant differences in the
HRs of MACEs in the remaining three quintiles.
Multivariate Cox regression analysis was used to
confirm these results. There was a significant interaction
(p<0.001) between the quintiles of propensity score and
treatment. The treatment covariates for MACEs resulted
in a significant effect of revascularisation methods,
mainly in the first and fifth quintiles. Interaction analysis
showed heterogeneities of the effects of treatment
depending on the revascularisation methods. This
model was used to test whether the HRs of each quintile
were significantly different from each other with respect
to the effect of revascularisation. There was a significant
interaction (p<0.001) between the first and the fifth
quintiles and treatment
All-cause mortality
In the first quintile, the 6-month death rate was 0% in the
revascularisation group and 24.7% in the medical therapy
group. There was a trend towards higher mortality among
patients who had undergone revascularisation in the fifth
quintile (HR 4.94; 95% CI 0.57 to 42.30; p=0.10). No rele-
vant differences were found in the remaining categories of
propensity scores (HR of the second quintile: 1.16; 95% CI
0.52 to 2.58; HR of the third quintile: 1.03; 95% CI 0.44 to
2.26 and HR of the fourth quintile: 0.68; 95% CI 0.22 to
2.09).
DISCUSSION
This study provides insights on real-life treatment of
patients who stabilised 48 h after an ACS. The research
question is relevant, as in a substantial number of
patients control of anginal symptoms, ECG changes and
haemodynamics are achieved with medical treatment
within the first 24 h. The use of propensity score as a
stratification method yielded new information on how
clinical variables may influence 6-month outcomes. The
principal finding is that outcomes in the great majority
of patients appear to be unaffected by treatment with
in-hospital coronary intervention.
Moreover, we found a significant reduction in cardio-
vascular endpoints associated with revascularisation,
compared with medical treatment in patients with oldest
age prior to myocardial infarction and renal failure and
an increased hazard in younger male patients with ST
elevation myocardial infarction and a family history of
coronary disease. There is, therefore, a strong and
robust heterogeneity in the treatment effects of an inva-
sive strategy in patients who have stabilised after an ACS.
Meaning of the study
The Clinical Outcomes Utilising Revascularisation and
Aggressive Drug Evaluation (COURAGE) trial found
that optimal medical therapy was just as good at prevent-
ing future events as receiving coronary revascularisation
added to optimal medical therapy in patients with stable
angina.11 However, the results of randomised trials do
not necessarily apply to other populations. The
Table 3 Subgroups analysis with Cox regression model
according to percentiles of the propensity score
Quintile
Patients in the medical therapy group
are the referent category
HR 95% CI p Value
First 0.81 0.66 to 0.99 0.041
Second 1.13 0.52 to 2.56 NS
Third 1.70 0.91 to 3.17 NS
Fourth 0.96 0.42 to 2.24 NS
Fifth 4.73 1.36 to 16.49 0.014
NS, non-significant.
Figure 1 Kaplan-Meier estimates of the cumulative event
rates (major acute cardiovascular events): in-hospital coronary
revascularisation group (––); medical therapy group (—). The
rate of the primary endpoint (unstable angina requiring
rehospitalisation, stroke, non-fatal myocardial infarction and
all-cause mortality) at 6 months was not significantly different
between the two groups (adjusted HR 1.41, 95% CI 0.98 to
2.04).
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COURAGE trial included a mixed population of patients
with and without prior ACS, but lacked information on
time to stabilisation from previous acute episodes to
accurately define the boundary between a potentially
stable and unstable cohort after an ACS.11
The objective of the current study was to formally test
the impact of medical therapy versus coronary revascu-
larisation added to medical therapy on the management
of patients with recent ACS who were stable for 48 h
after an ACS.
Methodological strengths of the study
In this population, we created a propensity score for the
likelihood of undergoing in-hospital revascularisation
using multiple logistic regressions with in-hospital revas-
cularisation condition as a dependent variable and base-
line clinical characteristics of the cohort as covariates
including the index event (table 1). The results of the
current study were therefore consistent among the two
diagnostic groups: STEMI and NSTACS.
Principal findings
The principal finding is that selection for in-hospital cor-
onary intervention was not associated with reduced risk
compared with medical therapy for the great majority of
patients who stabilised after an ACS (the second, third,
fourth and fifth quintiles, approximately 80% of the
overall study population). Our findings are congruent
with previous works that called into question the role of
routine revascularisation therapy for prevention of sub-
sequent cardiovascular events among many patients with
ACS.2 12–14 With regard to patients with STEMI, the
Occluded Artery Trial (OAT) found no discernible
benefit at 4-year follow-up among patients with occlusion
of the infarct-related artery following a strategy of
routine PCI 3–28 days after acute myocardial infarction.2
The findings of the OAT study, however, should not be
interpreted as applying to all patients experiencing ACS,
but just to a minority of ST elevation ACS patients: those
with no or minimal angina, one-vessel disease and
normal ejection fraction. In addition, the OAT study
investigated the effect of PCI on a 4-year outcome, so it
is not comparable with the results of this study, which
looked only at a 6-month outcome. With regard to
patients with NSTACS, a TACTICS-TIMI–18 trial post
hoc analysis demonstrated that patients with cardiac
troponin I levels of less than 0.1 ng/ml had no detect-
able benefit from early invasive management.15 This
study, however, lumped together patients with markedly
different clinical characteristics, including those patients
with recurrent ischaemic episodes of ischaemia and
serious ventricular arrhythmias who were not clearly in a
stable phase of their disease. Our results are more repre-
sentative of the treatment effects of an invasive strategy
in patients that can safely be stabilised in the coronary
care unit 48 h after an ACS. In these patients, the prog-
nosis is uncertain and the predictive value of troponin
determination has not yet been ascertained.
It is interesting that, in our study population, troponin
I could not differentiate patients who benefited from
coronary revascularisation (first quintile) from those
who did not (second, third and fourth quintiles), while
C reactive protein levels did so. Although the mechan-
ism underlying the present result cannot be established
by our data, previous works could offer a potential
explanation for these findings. A post hoc analysis of
patients enrolled in the Global Utilisation of Strategies
to Open Occluded Coronary Arteries IIb study has indi-
cated that the ‘front-loading’ of major coronary events
may be observed within the first 24 h.16 Accordingly,
cardiac troponin assay at admission is mainly a predictor
of major cardiac events within 48–72 h.17 In our study,
we defined a landmark time of 48 h; thus, we missed the
earliest occurrence of coronary events and the asso-
ciated predictor power of troponin. C reactive protein
might be a better discriminator of patients who remain
at high risk despite apparent stabilisation of their clinical
condition, as there is published evidence that elevations
in levels of C reactive protein predict the future risk of
myocardial infarction even in asymptomatic middle-aged
men and women with or without documented ischaemic
heart disease.18
Another important point of the study is that referral
to routine in-hospital elective revascularisation is asso-
ciated with decreased risk of cardiovascular endpoints in
approximately 20% of patients, specifically in patients of
the lowest-propensity stratum (first quintile). Patients of
the first quintile were the oldest, had higher serum cre-
atine levels and had a more significant history of prior
myocardial infarction as an index event. They also
showed the highest C reactive protein levels. Our results
are consistent with previous data. Observational studies
and trials of invasive versus medical therapy19 have
found that patients ≥75 years of age benefit more from
revascularisation than from optimised medical therapy
in terms of symptom relief and quality of life.
Elderly patients have greater disease severity, including
prior myocardial infarction and elevated creatinine
levels.19 20 It is well established that early revascularisa-
tion improves 1-year survival in patients with ACS and
renal insufficiency.19 The Veterans Affairs Non-Q-Wave
Infarction Strategies in Hospital trial is so far the only
trial on treatment according to previous myocardial
infarction. It demonstrated the superiority of an
early-invasive strategy in patients presenting with ACS
and prior myocardial infarction.21
A further finding of our study was to demonstrate the
superiority of freedom from adverse outcomes in the
highest-propensity stratum (fifth quintile) managed with
medical therapy alone. Patients in the revascularisation
group had a significantly higher risk for MACEs (HR
4.74; 95% CI 1.36 to 16.49) and a directionally consist-
ent but non-significantly higher odds of mortality (HR
4.94; 95% CI 0.57 to 42.30). These results clearly call for
further investigation. Indeed, there were no significant
data from previous works supporting the hypothesis that
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selected ACS patients might be harmed more from
in-hospital revascularisation. Patients of the fifth quintile
were young and prevalently male. They had the highest
proportions of ST elevation myocardial infarction as an
index event (50%) and a family history of coronary
artery disease (41.7%). A previous work has highlighted
the importance of male sex and family history in young
patients with acute myocardial infarction.19 We are not
aware of previous studies on clinical decision rules for
revascularisation in patients with a family history of cor-
onary artery disease. The results that we report herein
suggest that the use of revascularisation either with PCI
or CABG should be done cautiously. A number of expla-
nations could account for these results. The revasculari-
sation process is intrinsically inflammatory. Both
revascularisation strategies may induce a rapid increase
in plasma levels of C reactive protein, vascular cell adhe-
sion molecule-1 and chemokines.22–24 Patients with a
genetic predisposition to coronary disease may be espe-
cially vulnerable to these adverse effects as there is
increasing evidence that clusters of inflammatory factors
and markers of oxidation are associated with a positive
parental history of premature coronary heart disease in
youths.25–27
An additional explanation for the relatively poor prog-
nosis of patients undergoing revascularisation in the
fifth quintile comes from the design of our study. As we
defined a landmark time of 2 days, these patients were
referred for ‘late’ revascularisation after ACS. The effi-
cacy of late elective PCI in ST elevation myocardial
infarction has been assessed in the TAMI-6 (The
Thrombolysis and Angioplasty in Myocardial
Infarction)28 and TOAT (Open Artery Trial) trials.29
None of these trials supported the value of this
approach.28 29 In TAMI-6, angiography was performed
within 30–48 h after symptom onset.28 PCI was asso-
ciated with improved left ventricular ejection fraction at
1 month but not at 6 months. In the TOAT trial, angiog-
raphy was performed at 3 days to 4 weeks after the
infarction with PCI having an adverse effect on left ven-
tricular remodelling.29
Strengths and limitations of the study
The results of a randomised trial apply only to patients
meeting the study entry criteria and given the identical
treatment. It is without empirical evidence to expand
the results of a trial into a broad therapeutic principle.
It is simpler to demonstrate that routine in-hospital cor-
onary revascularisation generally works for patients with
ACS than it is to define precisely the population that
benefits.
The strength of the current study was, therefore, to
focus on those patients whose condition can safely be
stabilised in the coronary care unit providing key con-
textual data for identifying patients with poor outcomes
likely to benefit from coronary revascularisation therapy,
as well as providing initial estimates of the efficacy of
therapy.
Our study should be interpreted in the context of
several potential limitations. First, this study has no
power to detect differences between treatment groups in
the individual components of the primary composite
endpoint. Second, this analysis is not a randomised
study. Although the propensity score helps to adjust for
differences between groups, it does not control for
unmeasured differences in clinical care. However, as a
randomised trial cannot be carried out for every sub-
group of patients, an observational database is helpful in
providing hypothesis-generating data. Third, the median
age was 79.7 years in the first quintile. It is therefore pos-
sible that non-cardiovascular mortality contributed to
the total deaths, especially in this quintile. However,
referral to coronary revascularisation decreased cardio-
vascular endpoints and mortality as well in these
patients; thus, total mortality was most likely driven by
mortality from cardiovascular causes. Fourth, the limited
duration of follow-up may have obscured the possibility
of later benefit. Fifth, the use of observational data from
a single centre limits the generalisability of the findings.
Sixth, data were not available on the body mass index.
CONCLUSIONS
In summary, we used propensity score analysis and
observed a strong and robust heterogeneity in the treat-
ment effects of an invasive strategy, which was associated
with a significant reduction in cardiovascular endpoints
at 6 months among patients (first quintile) with the
oldest age, high-risk clinical features (prior myocardial
infarction and renal failure) and biochemical evidence
of a strong inflammatory activity (high C reactive
protein levels). Conversely, a routine in-hospital elective
revascularisation was not associated with reduced risk
over medical therapy in the majority of patients (second,
third, fourth and fifth quintiles). There was evidence of
an increased hazard with an invasive strategy in younger
male patients with ST elevation myocardial infarction
and a family history of coronary disease. If corroborated
by other studies, these findings may have profound clin-
ical implications on the contemporary management of
patients whose condition can safely be stabilised after an
ACS.
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